Abstract 1363P
Background
Patient selection in clinical trials is crucial but challenging, traditionally dependent on clinician-led identification that might overlook potential participants. We suggest an artificial intelligence (AI)-enhanced approach for institutional patient screening to improve trial enrolment.
Methods
This retrospective study analysed advanced lung cancer patients who attended Gustave Roussy between Feb 2021-Dec 2023. We automated the extraction and structuring of 83 variables from unstructured patient notes, including demographic, disease characteristics (histology, PD-L1 status, molecular and metastatic status), comorbidities, treatment history, and life status. Automated Data Entry (ADE) used advanced language model techniques, with prompt engineering and tailored few-shot examples, compared against Manual Data Entry (MDE) for accuracy. The primary goal was to assess ADE's accuracy of capturing data critical for determining trial eligibility. The method was tested to identify candidates for a phase I trial targeting advanced lung cancer patients with SMARCA4 alterations, pre-treated with ≥1 line of systemic therapy, and an ECOG status of 0-1.
Results
Of 1,057 patients screened, the median completeness of data per patient was 96.7%, with a processing time of 3 minutes per patient. Among 137 patients with both ADE and MDE, ADE achieved 96% accuracy. Of the 39 patients with SMARCA4 alterations, ADE identified 35 (90%), compared to 25 (64%) by MDE. ADE found 21 living patients with SMARCA4 alterations, 15 of whom had metastatic disease. It further identified 13 patients treated in advanced settings, including 8 with progression on ≥one line of therapy (potential candidates) and 5 on first-line chemo-immunotherapy without progression (potential waiting list candidates). After integrating the latest ECOG status, ADE accurately pre-screened 7 patients for the main criteria and 5 for the waiting list.
Conclusions
The AI-driven ADE method is feasible for pre-screening of lung cancer patients for precision medicine trials, achieving over 90% accuracy in identifying main eligibility criteria. This scalable approach could ensure more precise patient selection and optimize clinical trial matching.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
B. Besse, Institut Gustave Roussy, Villejuif, France.
Funding
Has not received any funding.
Disclosure
M. Aldea: Financial Interests, Personal and Institutional, Research Funding: AstraZeneca, Sandoz, Amgen. P. Rolland, A. Poplu, A. Djarallah, L. Chutto, B. Vignal, S. Platano: Financial Interests, Personal, Affiliate: Lifen. F. Le Ouay: Financial Interests, Personal, Ownership Interest: Lifen. All other authors have declared no conflicts of interest.
Resources from the same session
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06
1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Presenter: Alexander Meisel
Session: Poster session 06
1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Presenter: Andreas Koulouris
Session: Poster session 06